Bedard, Mary C.
Chihanga, Tafadzwa
Carlile, Adrean
Jackson, Robert http://orcid.org/0000-0001-9898-5546
Brusadelli, Marion G.
Lee, Denis
VonHandorf, Andrew
Rochman, Mark http://orcid.org/0000-0002-0818-927X
Dexheimer, Phillip J. http://orcid.org/0000-0003-3965-6894
Chalmers, Jeffrey http://orcid.org/0000-0003-1723-9774
Nuovo, Gerard
Lehn, Maria http://orcid.org/0000-0001-8400-7733
Williams, David E. J.
Kulkarni, Aditi
Carey, Molly
Jackson, Amanda
Billingsley, Caroline
Tang, Alice
Zender, Chad
Patil, Yash
Wise-Draper, Trisha M.
Herzog, Thomas J.
Ferris, Robert L.
Kendler, Ady
Aronow, Bruce J. http://orcid.org/0000-0001-5109-6514
Kofron, Matthew
Rothenberg, Marc E. http://orcid.org/0000-0001-9790-6332
Weirauch, Matthew T.
Van Doorslaer, Koenraad http://orcid.org/0000-0002-2985-0733
Wikenheiser-Brokamp, Kathryn A. http://orcid.org/0000-0002-2932-3095
Lambert, Paul F.
Adam, Mike http://orcid.org/0000-0003-4501-4740
Steven Potter, S. http://orcid.org/0000-0003-0726-0350
Wells, Susanne I. http://orcid.org/0000-0002-7234-676X
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (T32ES007250)
CancerFreeKids
The BI05 Institute
State of Arizona Improving Health TRIF
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA228113)
Article History
Received: 21 March 2022
Accepted: 15 March 2023
First Online: 8 April 2023
Competing interests
: R.L.F: Adagene Incorporated: Consulting; Aduro Biotech, Inc: Consulting, AstraZeneca/MedImmune: Clinical Trial, Research Funding; Bicara Therapeutics, Inc: Consultant; Bristol-Myers Squibb: Advisory Board, Clinical Trial, Research Funding; Brooklyn Immunotherapeutics LLC: Consultant; Catenion: Consultant; Coherus BioSciences, Inc.: Advisory Board; Eisai Europe Limited: Advisory Board; EMD Serono: Consultant; Everest Clinical Research Corporation: Consultant; F. Hoffmann-La Roche Ltd: Consultant; Federation Bio, Inc: Consultant; Genocea Biosciences, Inc: Consultant; Genmab: Advisory Board; Hookipa Biotech GmbH: Advisory Board; Instil Bio, Inc: Advisory Board; Kowa Research Institute, Inc.: Consultant; Lifescience Dynamics Limited: Advisory Board; MacroGenics, Inc.: Advisory Board; MeiraGTx, LLC: Advisory Board; Merck: Advisory Board, Clinical Trial; Mirati Therapeutics, Inc: Consultant; Mirror Biologics Inc: Supplementary Data Safety Monitoring Board; Nanobiotix: Consultant; Novartis Pharmaceutical Corporation: Consulting; Novasenta: Consulting, Stock, Research Funding; Numab Therapeutics AG: Advisory Board; OncoCyte Corporation: Advisory Board; Pfizer: Advisory Board; PPD Development, L.P.: Consultant; Rakuten Medical, Inc: Advisory Board; Sanofi: Consultant; Seagen, Inc: Advisory Board; SIRPant Immunotherapeutics, Inc: Advisory Board; Tesaro: Research Funding; Vir Biotechnology, Inc: Advisory Board; Zymeworks, Inc.: Consultant. T.J.H.: AstraZeneca, Caris, Clovis, Eisai, Genentech, GlaxoSmithKline, Immunogen, Johnson & Johnson, Merck, Mersana and Seagen (Advisory Boards). The remaining authors declare no competing interests.